SAB Biotherapeutics announced the appointment of Mark J. Ratain, MD, to the Company's Board of Scientific Advisors, to help advance SAB's oncology platform. Mark J. Ratain, MD, Leon O. Jacobson Professor of Medicine at The University of Chicago, is an expert in the use of investigational agents to treat advanced solid tumors, in addition to his specialty in the clinical pharmacology of marketed drugs. Dr. Ratain is an international leader in phase I clinical trials, pharmacogenetics and clinical trial methodology, and he created the new discipline of interventional pharmacoeconomics.

His work can be found in more than 500 published articles and book chapters. Dr. Ratain has an interest in the clinical development of new oncology drugs, and the focus of his recent research was on the use of pharmacogenomics to guide personalized prescribing and interventional pharmacoeconomics. He has also received awards for his research from multiple major academic societies, including the American Society for Clinical Oncology and the American Society for Clinical Pharmacology and Therapeutics, as well as from the Pharmaceutical Research and Manufacturers of America Foundation.